.jpg)
Two additional companies have recently joined the Tel Aviv Stock Exchange (TASE) High-Tech Analysis Project. They will join the 20 companies already reviewed by two international companies - Edison and Frost & Sullivan.
The additional companies are:
- Clal Biotechnology Industries - which invests in R&D companies in the field of life sciences and medical technology.
- Algomizer - which markets and develops software for automation and optimization of marketing and advertising services on the Internet, to agencies and advertisers.
Following is the list of the companies that are already participating in the project:
- Biomed companies - Intec Pharma, Allium, Aposense*, BioLight, BioLineRx*, BiondVax, Brainsway*, DNA Biomed*, Kitov* Cellect, Pluristem, Collplant and Redhill.
- Technology companies - Ellomay, Energix, Vonetize, Nano Dimension, Safe T, Pointer and Foresight.
Data from the TASE's research unit indicates that most of the companies participating in the project recorded a significant increase in trading volumes, compared to their volume in the months preceding publication of the initial analysis. Also, in dual-listed shares, trading volumes in the US also increased.
The overall trading turnover in most of the analyzed shares increased by 1.6 times and up to more than 10 times in this period (except for Foresight shares, where trading turnover increased 40 times, and Intec and Allium shares, where trading volumes declined during the period under review).
In addition, most companies recorded a significant increase in the holdings of mutual funds and Israeli institutional investors in the long term, and there was a greater interest of investors, which assisted in private placements and public offerings.
The participating companies enjoyed exposure to thousands of international investors from about 30 countries around the world, hundreds of which are institutional and sophisticated investors.
